Based on MRI showing a hyperplastic central glandular mass, a heterogeneous nodule with capsules, a 10 mm circumscribed T2‑hypointense lesion with moderate diffusion restriction and early contrast enhancement in the left base transition zone anterior (PI‑RADS 4), and a similar 14 mm lesion in the left middle transition zone peripheral, is this description consistent with Prostate Imaging Reporting and Data System (PI‑RADS) category 4 or category 3?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: May 20, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

PI-RADS Classification Assessment

The description is consistent with PI-RADS 4, not PI-RADS 3. The report explicitly identifies a 10 mm circumscribed T2-hypointense lesion with moderate diffusion restriction and early contrast enhancement in the left transition zone base as PI-RADS 4, and describes a similar 14 mm lesion with comparable characteristics in the left transition zone middle third 1.

Rationale for PI-RADS 4 Classification

Key Imaging Features Present

The described lesions demonstrate the critical combination of features that define PI-RADS 4 in the transition zone:

  • Circumscribed T2-hypointense appearance (T2 score indicating suspicion)
  • Moderate diffusion restriction (DWI score elevation)
  • Early contrast enhancement (DCE positivity serving as an upgrading factor)
  • Size ≥10 mm (both lesions meet detectability thresholds for clinically significant disease)

According to PI-RADS v2 criteria, transition zone lesions are primarily assessed based on T2-weighted imaging characteristics, with DWI having less emphasis compared to peripheral zone lesions 1. However, when a transition zone lesion shows both T2 abnormalities AND marked diffusion restriction with contrast enhancement, this combination warrants PI-RADS 4 designation 1.

Why Not PI-RADS 3?

PI-RADS 3 represents equivocal findings with intermediate likelihood of clinically significant prostate cancer. The description provided goes beyond equivocal:

  • The lesions are described as "circumscribed" rather than ill-defined
  • "Moderate diffusion inhibition" indicates DWI score ≥3-4
  • "Increased early contrast medium accumulation" provides additional positive DCE findings
  • The radiologist already assigned PI-RADS 4 to the first lesion, and the second lesion has "similar structural abnormality"

Clinical Context for Both Lesions

Research demonstrates that transition zone PI-RADS 4 lesions have approximately 48-62% positive predictive value for clinically significant prostate cancer 2. The presence of two separate lesions with similar characteristics (10 mm and 14 mm) both exhibiting the complete triad of T2 hypointensity, diffusion restriction, and early enhancement strongly supports PI-RADS 4 classification for both 3.

Important Caveats

Beware of atypical BPH nodules: One critical pitfall in transition zone assessment is the "2+1" lesion described in PI-RADS v2.1—atypical BPH nodules with incomplete capsules that show marked diffusion restriction. These are upgraded from PI-RADS 2 to 3, but have only 6% risk of clinically significant cancer 3. However, your description specifies circumscribed lesions without mention of incomplete capsules or overlying stromal hyperplasia, distinguishing them from this benign entity.

Overlying stromal hyperplasia: Transition zone PI-RADS 4 lesions with overlying signs of severe stromal hyperplasia have dramatically lower cancer detection rates (only 11% overall, 4% clinically significant) 2. The description does not mention this confounding feature for either lesion.

Management Implications

Both lesions warrant targeted biopsy. PI-RADS 4 lesions carry sufficient risk (approximately 50% for clinically significant disease) to justify MRI-targeted fusion biopsy combined with systematic sampling 2, 4. The 14 mm lesion, being larger and in a similar location with similar characteristics, should be treated with equal suspicion as the explicitly labeled PI-RADS 4 lesion.

Biopsy Strategy

  • Perform MRI/ultrasound fusion-guided targeted biopsy of both lesions (minimum 2-4 cores per lesion)
  • Include systematic 12-core sampling to avoid missing disease
  • Targeted biopsy alone can miss 7% of clinically significant cancers 2

If initial biopsy is negative: Consider rebiopsy for unambiguous peripheral zone PI-RADS 4 lesions, but transition zone lesions with overlying hyperplasia may be followed with repeat MRI instead 2. Given the circumscribed nature and lack of mentioned stromal hyperplasia in your case, rebiopsy would be appropriate if initial sampling is negative and clinical suspicion remains high.

References

Related Questions

In a male patient with MRI showing four PI‑RADS 4 prostate lesions (10 mm left base transition zone, 14 mm left mid transition zone, 4 mm right apex, and 4 mm left apex) and an intact prostatic capsule, what is the appropriate next step in management?
What is the recommended management for an adult male with a PI‑RADS 4 lesion in the mid gland of the prostate?
In a man over 50 with benign prostatic hyperplasia and lower urinary tract symptoms, can a transitional zone Prostate Imaging Reporting and Data System (PI-RADS) 4 lesion be caused by the BPH?
How likely is a left anterior peripheral zone mid-gland subcapsular prostate lesion measuring 1.3 × 0.5 × 0.9 cm, which is T2-weighted hypointense, shows restricted diffusion and early enhancement, to be cancerous?
What workup and treatment should be pursued for an 83-year-old male with an MRI demonstrating a PI-RADS 5 lesion with fused signal abnormality in the left prostate gland extending from the base to the apex and involving the left seminal vesicle more than the right?
After pleural drainage, how can hydropneumothorax be distinguished from lung entrapment?
What is the recommended approach to assess and supplement vitamin D in patients with nephrotic syndrome, including dosing, monitoring, and use of active vitamin D if needed?
How can I determine whether a low serum potassium result is falsely low (pseudohypokalemia) and what steps should be taken to confirm and manage it?
What peer‑reviewed studies compare nebulized epinephrine (adrenaline) with systemic tranexamic acid for the management of hemoptysis?
What are the recommended methotrexate dosing adjustments based on estimated creatinine clearance?
Is quetiapine safe to use as needed (PRN) on the day of induction of labor?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.